Planta Med 2011; 77(11): 1086-1098
DOI: 10.1055/s-0030-1270904
58th International Congress and Annual Meeting of the Society for Medicinal Plant and Natural Product Research (GA) – Dr. Willmar Schwabe Award Lecture
Mini Reviews
© Georg Thieme Verlag KG Stuttgart · New York

Botanical Drugs, Synergy, and Network Pharmacology: Forth and Back to Intelligent Mixtures

Jürg Gertsch1
  • 1Institute of Biochemistry and Molecular Medicine, University of Bern, Bern, Switzerland
Further Information

Publication History

received Nov. 30, 2010 revised February 9, 2011

accepted February 14, 2011

Publication Date:
16 March 2011 (online)


For centuries the science of pharmacognosy has dominated rational drug development until it was gradually substituted by target-based drug discovery in the last fifty years. Pharmacognosy stems from the different systems of traditional herbal medicine and its “reverse pharmacology” approach has led to the discovery of numerous pharmacologically active molecules and drug leads for humankind. But do botanical drugs also provide effective mixtures? Nature has evolved distinct strategies to modulate biological processes, either by selectively targeting biological macromolecules or by creating molecular promiscuity or polypharmacology (one molecule binds to different targets). Widely claimed to be superior over monosubstances, mixtures of bioactive compounds in botanical drugs allegedly exert synergistic therapeutic effects. Despite evolutionary clues to molecular synergism in nature, sound experimental data are still widely lacking to support this assumption. In this short review, the emerging concept of network pharmacology is highlighted, and the importance of studying ligand-target networks for botanical drugs is emphasized. Furthermore, problems associated with studying mixtures of molecules with distinctly different pharmacodynamic properties are addressed. It is concluded that a better understanding of the polypharmacology and potential network pharmacology of botanical drugs is fundamental in the ongoing rationalization of phytotherapy.


  • 1 Hopkins A L. Network pharmacology.  Nat Biotechnol. 2007;  25 1110-1111
  • 2 Hopkins A L. Network pharmacology: the next paradigm in drug discovery.  Nat Chem Biol. 2008;  4 682-690
  • 3 Altmann K H, Gertsch J. Anticancer drugs from nature–natural products as a unique source of new microtubule-stabilizing agents.  Nat Prod Rep. 2007;  24 327-357
  • 4 Gertsch J, Meier S, Tschopp N, Altmann K H. New tubulin inhibitors from plants: A critical assessment.  Chimia. 2007;  61 368-372
  • 5 Hansen O. Interaction of cardiac glycosides with (Na+ + K+)-activated ATPase. A biochemical link to digitalis-induced inotropy.  Pharmacol Rev. 1984;  36 143-163
  • 6 Prassas I, Diamandis E P. Novel therapeutic applications of cardiac glycosides.  Nat Rev Drug Discov. 2008;  7 926-935
  • 7 Prevatt-Smith K M, Prisinzano T E. New therapeutic potential for psychoactive natural products.  Nat Prod Rep. 2010;  27 23-31
  • 8 Fozzard H A, Lipkind G M. The tetrodotoxin binding site is within the outer vestibule of the sodium channel.  Mar Drugs. 2010;  8 219-234
  • 9 Nicolai E A. Rezepte und Kurarten mit theoretisch-praktischen Anmerkungen, von D. Ernst Anton Nicolai, Hofrath und Professor zu Jena, Vol. 4. Jena; Cröker 1788: 567
  • 10 Mann R D. From mithridatium to modern medicine: the management of drug safety.  J R Soc Med. 1988;  81 725-728
  • 11 Catellani P, Console R. The rise and fall of mithridatium and theriac in pharmaceutical texts.  Pharm Hist (Lond). 2007;  37 2-9
  • 12 Griffin J P. Venetian treacle and the foundation of medicines regulation.  Br J Clin Pharmacol. 2004;  58 317-325
  • 13 Bosch F, Rosich L. The contributions of Paul Ehrlich to pharmacology: a tribute on the occasion of the centenary of his Nobel Prize.  Pharmacology. 2008;  82 171-179
  • 14 Triggle D J. Pharmacological receptors: a century of discovery – and more.  Pharm Acta Helv. 2000;  74 79-84
  • 15 Crews C M. Targeting the undruggable proteome: the small molecules of my dreams.  Chem Biol. 2010;  17 551-555
  • 16 Karczmar A G. The Otto Loewi Lecture. Loewi's discovery and the XXI century.  Prog Brain Res. 1996;  109 1-27
  • 17 Hopkins A L, Mason J S, Overington J P. Can we rationally design promiscuous drugs?.  Curr Opin Struct Biol. 2006;  16 127-136
  • 18 Hunt J T. Discovery of ixabepilone.  Mol Cancer Ther. 2009;  8 275-281
  • 19 Möhler H. The rise of a new GABA pharmacology.  Neuropharmacology. DOI: 10.1016/j.neuropharm.2010.10.020 , advance online publication October 28, 2010
  • 20 Sternbach L H. The benzodiazepine story.  Prog Drug Res. 1978;  22 229-266
  • 21 Andersson T, Weidolf L. Stereoselective disposition of proton pump inhibitors.  Clin Drug Investig. 2008;  28 263-279
  • 22 Lurje G, Lenz H J. EGFR signaling and drug discovery.  Oncology. 2009;  77 400-410
  • 23 Morrow J K, Tian L, Zhang S. Molecular networks in drug discovery.  Crit Rev Biomed Eng. 2010;  38 143-156
  • 24 Chen B, Wild D, Guha R. PubChem as a source of polypharmacology.  J Chem Inf Model. 2009;  49 2044-2055
  • 25 Yang X, Huang Y, Crowson M, Li J, Maitland M L, Lussier Y A. Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data.  J Biomed Inform. 2010;  43 376-384
  • 26 Knight Z A, Lin H, Shokat K M. Targeting the cancer kinome through polypharmacology.  Nat Rev Cancer. 2010;  10 130-137
  • 27 Merino A, Bronowska A K, Jackson D B, Cahill D J. Drug profiling: knowing where it hits.  Drug Discov Today. 2010;  15 749-756
  • 28 Brötz-Oesterhelt H, Brunner N A. How many modes of action should an antibiotic have?.  Curr Opin Pharmacol. 2009;  8 564-573
  • 29 Kohanski M A, Dwyer D J, Collins J J. How antibiotics kill bacteria: from targets to networks.  Nat Rev Microbiol. 2010;  8 423-435
  • 30 Wagner H. Synergy research: approaching a new generation of phytopharmaceuticals.  Fitoterapia. 2011;  82 34-37
  • 31 Schmidt B M, Ribnicky D M, Lipsky P E, Raskin I. Revisiting the ancient concept of botanical therapeutics.  Nat Chem Biol. 2007;  3 360-366
  • 32 Griffith F L. A medical papyrus from Egypt.  Br Med J. 1893;  1 1172-1174
  • 33 Goltz D. Mittelalterliche Pharmazie und Medizin: dargestellt an Geschichte und Inhalt des Antidotarium Nicolai: mit einem Nachdruck der Druckfassung von 1471. Stuttgart; Wissenschaftliche Verlagsgesellschaft 1976: 136
  • 34 Qiu J. Traditional medicine: a culture in the balance.  Nature. 2007;  448 126-128
  • 35 Kong D X, Li X J, Zhang H Y. Where is the hope for drug discovery? Let history tell the future.  Drug Discov Today. 2009;  14 115-119
  • 36 Touwaide A, Pollio A, Aliotta G, Piomelli D, De Santo N G. Medicinal plants for the treatment of urogenital tract pathologies according to Dioscorides' De Materia Medica.  Am J Nephrol. 1997;  17 241-247
  • 37 Dowling H. Medicines for man. New York; Knopf 1973
  • 38 Shapiro A K. The placebo effect in the history of medical treatment: implications for psychiatry.  Am J Psychiatry. 1959;  116 298-304
  • 39 Patwardhan B, Vaidya D B, Chorghade M, Joshi S P. Reverse pharmacology and systems approaches for drug discovery and development.  Curr Bioact Compd. 2008;  4 201-212
  • 40 Leonti M, Casu L, Sanna F, Bonsignore L. A comparison of medicinal plant use in Sardinia and Sicily-De Materia Medica revisited?.  J Ethnopharmacol. 2009;  121 255-267
  • 41 Thomas E, Vanderbroek I, Goetghebeur P. The relationship between plant use and plant diversity in the Bolivian Andes, with special reference to medicinal plant use.  Hum Ecol. 2008;  36 861-879
  • 42 Moerman D E. Symbols and selectivity: a statistical analysis of native American medical ethnobotany.  J Ethnopharmacol. 1979;  1 111-119
  • 43 Moerman D E. An analysis of the food plants and drug plants of native North America.  J Ethnopharmacol. 1996;  52 1-22
  • 44 De Vos P. European materia medica in historical texts: longevity of a tradition and implications for future use.  J Ethnopharmacol. 2010;  132 28-47
  • 45 Moerman D E, Jonas W B. Deconstructing the placebo effect and finding the meaning response.  Ann Intern Med. 2002;  136 471-476
  • 46 Blanz M. [Placebos: aspects in medical history and approaches to definition].  Fortschr Neurol Psychiatr. 1991;  59 361-370
  • 47 Howlett A C. Reverse pharmacology applied to the cannabinoid receptor.  Trends Pharmacol Sci. 1990;  11 395-397
  • 48 Breinbauer R, Vetter I R, Waldmann H. From protein domains to drug candidates-natural products as guiding principles in the design and synthesis of compound libraries.  Angew Chem Int Ed Engl. 2002;  41 2879-2890
  • 49 Cragg G M, Newman D J, Snader K M. Natural products in drug discovery and development.  J Nat Prod. 1997;  60 52-60
  • 50 La Clair J J. Natural product mode of action (MOA) studies: a link between natural and synthetic worlds.  Nat Prod Rep. 2010;  27 969-995
  • 51 Thornburg C C, Zabriskie T M, McPhail K L. Deep-sea hydrothermal vents: potential hot spots for natural products discovery?.  J Nat Prod. 2010;  73 489-499
  • 52 Potterat O, Hamburger M. Drug discovery and development with plant-derived compounds.  Prog Drug Res. 2008;  65 45-118
  • 53 Etkin N L. Perspectives in ethnopharmacology: forging a closer link between bioscience and traditional empirical knowledge.  J Ethnopharmacol. 2001;  76 177-182
  • 54 Adams M, Berset C, Kessler M, Hamburger M. Medicinal herbs for the treatment of rheumatic disorders–a survey of European herbals from the 16th and 17th century.  J Ethnopharmacol. 2009;  121 343-359
  • 55 Verpoorte R, Crommelin D, Danhof M, Gilissen L J, Schuitmaker H, van der Greef J, Witkamp R F. Commentary: “A systems view on the future of medicine: inspiration from Chinese medicine?”.  J Ethnopharmacol. 2009;  121 479-481
  • 56 Sagen A L, Gertsch J, Becker R, Heilmann J, Sticher O. Quinolizidine alkaloids from the curare adjuvant Clathrotropis glaucophylla.  Phytochemistry. 2002;  61 975-978
  • 57 Gratus C, Wilson S, Greenfield S M, Damery S L, Warmington S A, Grieve R, Steven N M, Routledge P. The use of herbal medicines by people with cancer: a qualitative study.  BMC Complement Alternat Med. 2009;  9 14
  • 58 Neldner K H. Complementary and alternative medicine.  Dermatol Clin. 2000;  18 189-193
  • 59 World Health Organization .Traditional, complementary and alternative medicines and therapies. Washington DC; WHO Regional Office for the Americas/Pan American Health Organization (Working group OPS/OMS) 1999
  • 60 World Health Organization .Traditional medicine. Available at. Accessed January 15, 2010
  • 61 Graziose R, Lila M A, Raskin I. Merging traditional Chinese medicine with modern drug discovery technologies to find novel drugs and functional foods.  Curr Drug Discov Technol. 2010;  7 2-12
  • 62 Eng C. Are herbal medicines ripe for the cancer clinic?.  Sci Transl Med. 2010;  2 45ps41
  • 63 Lam W, Bussom S, Guan F, Jiang Z, Zhang W, Gullen E A, Liu S H, Cheng Y C. The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity.  Sci Transl Med. 2010;  2 45-59
  • 64 Melzer J, Brignoli R, Diehm C, Reichling J, Do D D, Saller R. Treating intermittent claudication with Tibetan medicine Padma 28: does it work?.  Atherosclerosis. 2006;  189 39-46
  • 65 Melzer J, Schrader E, Brattström A, Schellenberg R, Saller R. Fixed herbal drug combination with and without butterbur (Ze 185) for the treatment of patients with somatoform disorders: randomized, placebo-controlled pharmaco-clinical trial.  Phytother Res. 2009;  23 1303-1308
  • 66 Rodd R. Snuff synergy: preparation, use and pharmacology of yopo and Banisteriopsis caapi among the Piaroa of southern Venezuela.  J Psychoactive Drugs. 2002;  34 273-279
  • 67 Gable R S. Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids.  Addiction. 2007;  102 24-34
  • 68 Nahrstedt A, Butterweck V. Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).  J Nat Prod. 2010;  73 1015-1021
  • 69 Ulrich-Merzenich G, Panek D, Zeitler H, Vetter H, Wagner H. Drug development from natural products: exploiting synergistic effects.  Indian J Exp Biol. 2010;  48 208-219
  • 70 Liu R H. Potential synergy of phytochemicals in cancer prevention: mechanism of action.  J Nutr. 2004;  134 (Suppl. 12 ) 3479S-3485S
  • 71 Liao Z G, Liang X L, Zhu J Y, Zhao G W, Yang M, Wang G F, Jiang Q Y, Chen X L. Correlation between synergistic action of Radix Angelica dahurica extracts on analgesic effects of Corydalis alkaloid and plasma concentration of dl-THP.  J Ethnopharmacol. 2010;  129 115-120
  • 72 Wagner H. Synergy research: a new approach to evaluating the efficacy of herbal mono-drug extracts and their combinations.  Nat Prod Commun. 2009;  4 303-304
  • 73 Hellmann J K, Münter S, Wink M, Frischknecht F. Synergistic and additive effects of epigallocatechin gallate and digitonin on Plasmodium sporozoite survival and motility.  PLoS One. 2010;  5 e8682
  • 74 Wang L, Zhou G B, Liu P, Song J H, Liang Y, Yan X J, Xu F, Wang B S, Mao J H, Shen Z X, Chen S J, Chen Z. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia.  Proc Natl Acad Sci USA. 2008;  105 4826-4831
  • 75 Wang Y, Qin Q, Chen J, Kuang X, Xia J, Xie B, Wang F, Liang H, Qi Z. Synergistic effects of Isatis tinctoria L. and tacrolimus in the prevention of acute heart rejection in mice.  Transpl Immunol. 2009;  22 5-11
  • 76 Shi Q, Liu Z, Yang Y, Geng P, Zhu Y Y, Zhang Q, Bai F, Bai G. Identification of anti-asthmatic compounds in Pericarpium citri reticulatae and evaluation of their synergistic effects.  Acta Pharmacol Sin. 2009;  30 567-575
  • 77 Lin F M, Chen L R, Lin E H, Ke F C, Chen H Y, Tsai M J, Hsiao P W. Compounds from Wedelia chinensis synergistically suppress androgen activity and growth in prostate cancer cells.  Carcinogenesis. 2007;  28 2521-2529
  • 78 Ginsburg I, Sadovnik M, Sallon S, Milo-Goldzweig I, Mechoulam R, Breuer A, Gibbs D, Varani J, Roberts S, Cleator E, Singh N. 47PADMA-28, a traditional Tibetan herbal preparation inhibits the respiratory burst in human neutrophils, the killing of epithelial cells by mixtures of oxidants and pro-inflammatory agonists and peroxidation of lipids.  Inflammopharmacology. 1999;  7 47-62
  • 79 Chicca A, Raduner S, Pellati F, Strompen T, Altmann K H, Schoop R, Gertsch J. Synergistic immunomopharmacological effects of N-alkylamides in Echinacea purpurea herbal extracts.  Int Immunopharmacol. 2009;  9 850-858
  • 80 HemaIswarya S, Doble M. Potential synergism of natural products in the treatment of cancer.  Phytother Res. 2006;  20 239-249
  • 81 Gathirwa J W, Rukunga G M, Mwitari P G, Mwikwabe N M, Kimani C W, Muthaura C N, Kiboi D M, Nyangacha R M, Omar S A. Traditional herbal antimalarial therapy in Kilifi District, Kenya.  J Ethnopharmacol. 2011;  134 434-442
  • 82 Fiebich B L, Knörle R, Appel K, Kammler T, Weiss G. Pharmacological studies in an herbal drug combination of St. John's Wort (Hypericum perforatum) and passion flower (Passiflora incarnata): In vitro and in vivo evidence of synergy between Hypericum and Passiflora in antidepressant pharmacological models.  Fitoterapia. 2011;  82 474-480
  • 83 Adams L S, Seeram N P, Hardy M L, Carpenter C, Heber D. Analysis of the interactions of botanical extract combinations against the viability of prostate cancer cell lines.  Evid Based Complement Alternat Med. 2006;  3 117-124
  • 84 Berenbaum M C. What is synergy?.  Pharmacol Rev. 1989;  41 93-141
  • 85 Hastings I. How artemisinin-containing combination therapies slow the spread of antimalarial drug resistance.  Trends Parasitol. 2011;  27 67-72
  • 86 Gatti A, Sabato E, Di Paolo A R, Mammucari M, Sabato A F. Oxycodone/paracetamol: a low-dose synergic combination useful in different types of pain.  Clin Drug Investig. 2010;  30 3-14
  • 87 MacPherson R D. The pharmacological basis of contemporary pain management.  Pharmacol Ther. 2000;  88 163-185
  • 88 Bansal T, Akhtar N, Jaggi M, Khar R K, Talegaonkar S. Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation.  Drug Discov Today. 2009;  14 1067-1074
  • 89 Bebrone C, Lassaux P, Vercheval L, Sohier J S, Jehaes A, Sauvage E, Galleni M. Current challenges in antimicrobial chemotherapy: focus on beta-lactamase inhibition.  Drugs. 2010;  70 651-679
  • 90 Atal C K, Zutshi U, Rao P G. Scientific evidence on the role of Ayurvedic herbals on bioavailability of drugs.  J Ethnopharmacol. 1981;  4 229-232
  • 91 Efferth T, Koch E. Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy.  Curr Drug Targets. 2011;  12 122-132
  • 92 Wang S P, Liu L, Wang L L, Jiang P, Zhang J Q, Zhang W D, Liu R H. Screening and analysis of the multiple absorbed bioactive components and metabolites in rat plasma after oral administration of Jitai tablets by high-performance liquid chromatography/diode-array detection coupled with electrospray ionization tandem mass spectrometry.  Rapid Commun Mass Spectrom. 2010;  24 1641-1652
  • 93 Atal C K, Dubey R K, Singh J. Biochemical basis of enhanced drug bioavailability by piperine: evidence that piperine is a potent inhibitor of drug metabolism.  J Pharmacol Exp Ther. 1985;  232 258-262
  • 94 Anand P, Thomas S G, Kunnumakkara A B, Sundaram C, Harikumar K B, Sung B, Tharakan S T, Misra K, Priyadarsini I K, Rajasekharan K N, Aggarwal B B. Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature.  Biochem Pharmacol. 2008;  76 1590-1611
  • 95 Hu G, Baker S P. Trends in unintentional injury deaths, U.S., 1999–2005: age, gender, and racial/ethnic differences.  Am J Prev Med. 2009;  37 188-194
  • 96 Colalto C. Herbal interactions on absorption of drugs: Mechanisms of action and clinical risk assessment.  Pharmacol Res. 2010;  62 207-227
  • 97 Madabushi R, Frank B, Drewelow B, Derendorf H, Butterweck V. Hyperforin in St. John's wort drug interactions.  Eur J Clin Pharmacol. 2006;  62 225-233
  • 98 Zhou S F, Xue C C, Yu X Q, Wang G. Metabolic activation of herbal and dietary constituents and its clinical and toxicological implications: an update.  Curr Drug Metab. 2007;  8 526-553
  • 99 Zeng Z P, Jiang J G. Analysis of the adverse reactions induced by natural product-derived drugs.  Br J Pharmacol. 2010;  159 1374-1391
  • 100 Roeder E, Wiedenfeld H. Pyrrolizidine alkaloids in medicinal plants of Mongolia, Nepal and Tibet.  Pharmazie. 2009;  64 699-716
  • 101 Heinrich M, Chan J, Wanke S, Neinhuis C, Simmonds M S. Local uses of Aristolochia species and content of nephrotoxic aristolochic acid 1 and 2–a global assessment based on bibliographic sources.  J Ethnopharmacol. 2009;  125 108-144
  • 102 Berenbaum M C. Synergy assessment with growth curves.  J Infect Dis. 1984;  150 304
  • 103 Berenbaum M C. Minor synergy and antagonism may be clinically important.  J Antimicrob Chemother. 1987;  19 271-273
  • 104 Leão P N, Pereira A R, Liu W T, Ng J, Pevzner P A, Dorrestein P C, König G M, Vasconcelos V M, Gerwick W H. Synergistic allelochemicals from a freshwater cyanobacterium.  Proc Natl Acad Sci USA. 2010;  107 11183-11188
  • 105 Shiojiri K, Ozawa R, Kugimiya S, Uefune M, van Wijk M, Sabelis M W, Takabayashi J. Herbivore-specific, density-dependent induction of plant volatiles: honest or “cry wolf” signals?.  PLoS One. 2010;  5 e12161
  • 106 Kessler A, Baldwin I T. Defensive function of herbivore-induced plant volatile emissions in nature.  Science. 2001;  291 2141-2144
  • 107 Gertsch J, Tobler R T, Brun R, Sticher O, Heilmann J. Antifungal, antiprotozoal, cytotoxic and piscicidal properties of Justicidin B and a new arylnaphthalide lignan from Phyllanthus piscatorum.  Planta Med. 2003;  69 420-424
  • 108 Corning P A. The synergism hypothesis: on the concept of synergy and it's role in the evolution of complex systems.  J Soc Evol Syst. 1998;  21 133-172
  • 109 McLean S, Duncan A J. Pharmacological perspectives on the detoxification of plant secondary metabolites: implications for ingestive behavior of herbivores.  J Chem Ecol. 2006;  32 1213-1228
  • 110 Yang C S, Lambert J D, Sang S. Antioxidative and anti-carcinogenic activities of tea polyphenols.  Arch Toxicol. 2009;  83 11-21
  • 111 Zhang H Y, Chen L L, Li X J, Zhang J. Evolutionary inspirations for drug discovery.  Trends Pharmacol Sci. 2010;  31 443-448
  • 112 Firn R D, Jones C G. A Darwinian view of metabolism: molecular properties determine fitness.  J Exp Bot. 2009;  60 719-726
  • 113 Firn R D, Jones C G. Natural products–a simple model to explain chemical diversity.  Nat Prod Rep. 2003;  20 382-391
  • 114 Ewers R M, Thorpe S, Didham R K. Synergistic interactions between edge and area effects in a heavily fragmented landscape.  Ecology. 2007;  88 96-106
  • 115 Schoenian I, Spiteller M, Ghaste M, Wirth R, Herz H, Spiteller D. Chemical basis of the synergism and antagonism in microbial communities in the nests of leaf-cutting ants.  Proc Natl Acad Sci USA. , [in press]
  • 116 Hu Y, Platzer E G, Bellier A, Aroian R V. Discovery of a highly synergistic anthelmintic combination that shows mutual hypersusceptibility.  Proc Natl Acad Sci USA. 2010;  107 5955-5960
  • 117 Firn R D, Jones C G. The evolution of secondary metabolism – a unifying model.  Mol Microbiol. 2000;  37 989-994
  • 118 Cordell G A, Colvard M D. Some thoughts on the future of ethnopharmacology.  J Ethnopharmacol. 2005;  100 5-14
  • 119 de Sá Alves F R, Barreiro E J, Fraga C A. From nature to drug discovery: the indole scaffold as a “privileged structure”.  Mini Rev Med Chem. 2009;  9 782-793
  • 120 Fischbach M A, Clardy J. One pathway, many products.  Nat Chem Biol. 2007;  3 353-355
  • 121 Fischbach M A, Walsh C T, Clardy J. The evolution of gene collectives: How natural selection drives chemical innovation.  Proc Natl Acad Sci USA. 2008;  105 4601-4608
  • 122 Gertsch J, Leonti M, Raduner S, Racz I, Chen J Z, Xie X Q, Altmann K H, Karsak M, Zimmer A. Beta-caryophyllene is a dietary cannabinoid.  Proc Natl Acad Sci USA. 2008;  105 9099-9104
  • 123 Moussaieff A, Mechoulam R. Boswellia resin: from religious ceremonies to medical uses; a review of in vitro, in vivo and clinical trials.  J Pharm Pharmacol. 2009;  61 1281-1293
  • 124 Perry N, Perry E. Aromatherapy in the management of psychiatric disorders: clinical and neuropharmacological perspectives.  CNS Drugs. 2006;  20 257-280
  • 125 Romics I, Siller G, Kohnen R, Mavrogenis S, Varga J, Holman E. A special terpene combination (Rowatinex®) improves stone clearance after extracorporeal shockwave lithotripsy in urolithiasis patients: results of a placebo-controlled randomised controlled trial.  Urol Int. , [in press]
  • 126 Kohlert C, van Rensen I, März R, Schindler G, Graefe E U, Veit M. Bioavailability and pharmacokinetics of natural volatile terpenes in animals and humans.  Planta Med. 2000;  66 495-505
  • 127 Buckle J. Use of aromatherapy as a complementary treatment for chronic pain.  Alternat Ther Health Med. 1999;  5 42-51
  • 128 Wink M. Evolution of secondary metabolites from an ecological and molecular phylogenetic perspective.  Phytochemistry. 2003;  64 3-19
  • 129 McFrederick Q S, Fuentes J D, Roulston T, Kathilankal J C, Lerdau M. Effects of air pollution on biogenic volatiles and ecological interactions.  Oecologia. 2009;  160 411-420
  • 130 Busch B, Hertweck C. Evolution of metabolic diversity in polyketide-derived pyrones: using the non-colinear aureothin assembly line as a model system.  Phytochemistry. 2009;  70 1833-1840
  • 131 Bode H B, Bethe B, Höfs R, Zeeck A. Big effects from small changes: possible ways to explore nature's chemical diversity.  Chembiochem. 2002;  3 619-627
  • 132 Williamson E M. Synergy and other interactions in phytomedicines.  Phytomedicine. 2001;  8 401-409
  • 133 Ulrich-Merzenich G, Panek D, Zeitler H, Wagner H, Vetter H. New perspectives for synergy research with the “omic”-technologies.  Phytomedicine. 2009;  16 495-508
  • 134 Tong A H Y, Evangelista M, Parsons A B, Xu H, Bader G D, Pagé N, Robinson M, Raghibizadeh S, Hogue C W V, Bussey H, Andrews B, Tyers M, Boone C. Systematic genetic analysis with ordered arrays of yeast deletion mutants.  Science. 2001;  294 2364-2368
  • 135 Yeh P, Tschumi A I, Kishony R. Functional classification of drugs by properties of their pairwise interactions.  Nat Genet. 2006;  38 489-494
  • 136 Gertsch J, Viveros-Paredes J M, Taylor P. Plant immunostimulants—Scientific paradigm or myth?.  J Ethnopharmacol. DOI: 10.1016/j.jep.2010.06.044 , advance online publication July 8 2010
  • 137 Ríos J L, Recio M C, Escandell J M, Andújar I. Inhibition of transcription factors by plant-derived compounds and their implications in inflammation and cancer.  Curr Pharm Des. 2009;  15 1212-1237
  • 138 Yeh P, Kishony R. Networks from drug-drug surfaces.  Mol Syst Biol. 2007;  3 85
  • 139 Fitzgerald J B, Schoeberl B, Nielsen U B, Sorger P K. Systems biology and combination therapy in the quest for clinical efficacy.  Nat Chem Biol. 2006;  2 458-466
  • 140 Lehár J, Krueger A S, Avery W, Heilbut A M, Johansen L M, Price E R, Rickles R J, Short 3rd G F, Staunton J E, Jin X, Lee M S, Zimmermann G R, Borisy A A. Synergistic drug combinations tend to improve therapeutically relevant selectivity.  Nat Biotechnol. 2009;  27 659-666
  • 141 Rollinger J M, Schuster D, Danzl B, Schwaiger S, Markt P, Schmidtke M, Gertsch J, Raduner S, Wolber G, Langer T, Stuppner H. In silico target fishing for rationalized ligand discovery exemplified on constituents of Ruta graveolens.  Planta Med. 2009;  75 195-204
  • 142 Leonti M, Cabras S, Weckerle C S, Solinas M N, Casu L. The causal dependence of present plant knowledge on herbals – contemporary medicinal plant use in Campania (Italy) compared to Matthioli (1568).  J Ethnopharmacol. 2010;  130 379-391
  • 143 Pollio A, De Natale A, Appetiti E, Aliotta G, Touwaide A. Continuity and change in the Mediterranean medical tradition: Ruta spp. (Rutaceae) in Hippocratic medicine and present practices.  J Ethnopharmacol. 2008;  116 469-482
  • 144 Minker E, Bartha C, Rózsa Z, Szendrei K, Reisch J. Antispasmogenic effect of rutamarin and arborinine on isolated smooth muscle organs.  Planta Med. 1979;  37 156-160
  • 145 Golub T R. Mining the genome for combination therapies.  Nat Med. 2003;  9 510-511
  • 146 Gao J L, He T C, Li Y B, Wang Y T. A traditional Chinese medicine formulation consisting of Rhizoma Corydalis and Rhizoma Curcumae exerts synergistic anti-tumor activity.  Oncol Rep. 2009;  22 1077-1083
  • 147 Gertsch J. How scientific is the science in ethnopharmacology? Historical perspectives and epistemological problems.  J Ethnopharmacol. 2009;  122 177-183
  • 148 Woelkart K, Feizlmayr E, Dittrich P, Beubler E, Pinl F, Suter A, Bauer R. Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans.  Phytother Res. 2010;  24 445-450
  • 149 Woelkart K, Frye R F, Derendorf H, Bauer R, Butterweck V. Pharmacokinetics and tissue distribution of dodeca-2E,4E,8E,10E/Z-tetraenoic acid isobutylamides after oral administration in rats.  Planta Med. 2009;  75 1306-1313
  • 150 He S M, Li C G, Liu J P, Chan E, Duan W, Zhou S F. Disposition pathways and pharmacokinetics of herbal medicines in humans.  Curr Med Chem. 2010;  17 4072-4113
  • 151 Feng C, Liu M, Shi X, Yang W, Kong D, Duan K, Wang Q. Pharmacokinetic properties of paeoniflorin, albiflorin and oxypaeoniflorin after oral gavage of extracts of Radix Paeoniae Rubra and Radix Paeoniae Alba in rats.  J Ethnopharmacol. 2010;  130 407-413
  • 152 Butterweck V, Liefländer-Wulf U, Winterhoff H, Nahrstedt A. Plasma levels of hypericin in presence of procyanidin B2 and hyperoside: a pharmacokinetic study in rats.  Planta Med. 2003;  69 189-192
  • 153 Xu F, Liu Y, Dong H, Song R, Zhang Z. Pharmacokinetic comparison in rats of six bioactive compounds between Da-Cheng-Qi decoction and its parent herbal medicines.  Nat Prod Commun. 2010;  5 795-800
  • 154 Wegener T, Wagner H. The active components and the pharmacological multi-target principle of STW 5 (Iberogast).  Phytomedicine. 2006;  13 (Suppl. 5) 20-35
  • 155 Wang X, Wang Z, Sun H, Lv H, Guan H, Meng X, Sun H, Zhang G, Cao H. Pharmacokinetics of cimifugin in rat plasma after oral administration of the extract of Saposhnikovia divaricatae root. Determination of cimifugin by high performance liquid chromatography coupled with solid phase extraction.  Arzneimittelforschung. 2008;  58 445-450
  • 156 Lv H, Sun H, Sun W, Liu L, Wang P, Wang X, Cao H. Pharmacokinetic studies of a Chinese triple herbal drug formula.  Phytomedicine. 2008;  15 993-1001
  • 157 Schmid B, Kötter I, Heide L. Pharmacokinetics of salicin after oral administration of a standardised willow bark extract.  Eur J Clin Pharmacol. 2001;  57 387-391
  • 158 He S M, Li C G, Liu J P, Chan E, Duan W, Zhou S F. Disposition pathways and pharmacokinetics of herbal medicines in humans.  Curr Med Chem. , [in press]
  • 159 López-Moreno C A. Poster O26 “Phytotherapy of malignant and benign tumors with mixtures of extracts of angiosperms from arid zones of North of Mexico”. Naples; Natural Products in Cancer Therapy 2008
  • 160 Schmidt B, Ribnicky D M, Poulev A, Logendra S, Cefalu W T, Raskin I. A natural history of botanical therapeutics.  Metabolism. 2008;  57 S3-S9
  • 161 Kneifel W, Czech E, Kopp B. Microbial contamination of medicinal plants–a review.  Planta Med. 2002;  68 5-15
  • 162 Hamburger M. New approaches in analyzing the pharmacological properties of herbal extracts.  Proc West Pharmacol Soc. 2007;  50 156-161
  • 163 Wolfender J L, Ndjoko K, Hostettmann K. Liquid chromatography with ultraviolet absorbance-mass spectrometric detection and with nuclear magnetic resonance spectroscopy: a powerful combination for the on-line structural investigation of plant metabolites.  J Chromatogr A. 2003;  1000 437-455
  • 164 Wang J, van der Heijden R, Spijksma G, Reijmers T, Wang M, Xu G, Hankemeier T, van der Greef J. Alkaloid profiling of the Chinese herbal medicine Fuzi by combination of matrix-assisted laser desorption ionization mass spectrometry with liquid chromatography-mass spectrometry.  J Chromatogr A. 2009;  1216 2169-2178
  • 165 Wang J, van der Heijden R, Spruit S, Hankermeier T, Chan K, van der Greef J, Xu G, Wang M. Quality and safety of Chinese herbal medicines guided by a systems biology perspective.  J Ethnopharmacol. 2009;  126 31-41
  • 166 Yu W L, Guizzunti G, Foley T L, Burkart M D, La Clair J J. An optimized immunoaffinity fluorescent method for natural product target elucidation.  J Nat Prod. , [in press]
  • 167 Rosén J, Gottfries J, Muresan S, Backlund A, Oprea T I. Novel chemical space exploration via natural products.  J Med Chem. 2009;  52 1953-1962
  • 168 Jaki B U, Franzblau S G, Chadwick L R, Lankin D C, Zhang F, Wang Y, Pauli G F. Purity-activity relationships of natural products: the case of anti-TB active ursolic acid.  J Nat Prod. 2008;  71 1742-1748
  • 169 Vornholt W, Hartmann M, Keusgen M. SPR studies of carbohydrate-lectin interactions as useful tool for screening on lectin sources.  Biosens Bioelectron. 2007;  22 2983-2988
  • 170 Miyazaki I, Simizu S, Osada H. The application of the chemical array for biological study.  Methods Mol Biol. 2010;  669 95-107
  • 171 van Breemen R B, Li Y. Caco-2 cell permeability assays to measure drug absorption.  Expert Opin Drug Metab Toxicol. 2005;  1 175-185
  • 172 Bohlin L, Göransson U, Alsmark C, Wedén C, Backlund A. Natural products in modern life science.  Phytochem Rev. 2010;  9 279-301
  • 173 Larkins N, Wynn S. Pharmacognosy: phytomedicines and their mechanisms.  Vet Clin North Am Small Anim Pract. 2004;  34 291-327

Prof. Dr. Jürg Gertsch

Institute of Biochemistry and Molecular Medicine
University of Bern

Bühlstrasse 28

3012 Bern


Phone: +41 3 16 31 41 24

Fax: +41 3 16 31 37 37